The Proton Pump Inhibitor (PPI) Test for the Extraesophageal Manifestation of GERD

Samsung Medical Center100 enrolled

Overview

PPI test;empirical trial with high-dose proton-pump inhibitors (PPIs) has been shown to be a sensitive tool for diagnosing patients with GERD. However, this diagnostic strategy has not been well established in patients with extraesophageal manifestation of GERD. In this study, we aim to see the relevance of PPI test in diagnosing GERD in patients with extraesophageal symptoms.

Study Type

INTERVENTIONAL

Purpose

DIAGNOSTIC

Masking

NONE

Enrollment

100

Conditions

Gastroesophageal Reflux Disease

Interventions

Proton pump inhibitor (rabeprazole)DRUG

Patients receives rabeprazole 20mg AM and 20mg PM for 14 days

Eligibility

Sex: ALLMin age: 20 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with extraesophageal manifestation symptoms of GERD Exclusion Criteria: * laryngeal, pharyngeal, liver, lung, renal, or hematological disorders * a history of gastrointestinal surgery, and a history of connective tissue disorders. * patients with duodenal or gastric ulcers as well as other significant lesions, such as gastric cancer, esophageal cancer, or subepithelial tumors more than 1 cm observed on the upper endoscopy

Locations (1)

Samsung Medical Center, Sungkyunkwan University School of Medicine

Seoul, Gangnam-gu, South Korea

RECRUITING

Outcomes

Primary Outcomes

Symptom responders after PPI trials

Time frame: 2 weeks after PPI trials

Central Contacts

Tae ggon Kim

CONTACT

+82-2-3410-2975 tggo.kim@samsung.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.